

## Article

# Antimicrobial Efficacy of Phyto-L, Thiosulfonate from *Allium* spp. Containing Supplement, against *Escherichia Coli* Strains from Rabbits

Francesco D'Amico <sup>1</sup>, Gaia Casalino <sup>1</sup>, Francesca Rita Dinardo <sup>1</sup>, Michele Schiavitto <sup>2</sup>, Antonio Camarda <sup>1</sup>, Diana Romito <sup>1</sup>, Antonella Bove <sup>1</sup> and Elena Circella <sup>1,\*</sup>

<sup>1</sup> Department of Veterinary Medicine, University of Bari "Aldo Moro", S. P. Casamassima km 3, 70010 Valenzano, BA, Italy; francesco.damico@uniba.it (F.D.); gaia.casalino@uniba.it (G.C.); francesca.dinardo20@gmail.com (F.R.D.); antonio.camarda@uniba.it (A.C.); diana.romito@uniba.it (D.R.); antonella.bove@uniba.it (A.B.)

<sup>2</sup> Italian Rabbit Breeders Association—ANCI, Contrada Giancola snc, 71030 Volturara Appula, FG, Italy; micheleschiavitto@anci-aia.it

\* Correspondence: elena.circella@uniba.it; Tel./Fax: +39-080-467-9910

**Simple Summary:** The aim of this study was to evaluate the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of Phyto-L (Pro Tech s.r.l.), a commercial product containing organosulfur compounds (OSCs) such as propyl propane thiosulfonate (PTSO) from *Allium* spp., on 108 enteropathogenic *E. coli* (EPEC) strains responsible for colibacillosis in rabbits. Bacterial suspensions with a charge of  $10^8$  CFU/mL were tested with different concentrations (20, 10, 5, 2.5, 1.25, 0.6, 0.3, and 0.15  $\mu$ L/mL) of Phyto-L. To evaluate MBC values, bacterial suspensions corresponding to the MIC and above the MIC were plated on Tryptic Soy agar (TSA) without Phyto-L. The MICs of the tested strains corresponded to 1.25  $\mu$ L/mL (37/108-34.3%), 2.5  $\mu$ L/mL (70/108-64.8%), and 5  $\mu$ L/mL (1/108-0.9%). The MBCs were 1.25  $\mu$ L/mL (15/108-13.9%), 2.5  $\mu$ L/mL (46/108-42.6%), 5  $\mu$ L/mL (9/108-8.3%), 10  $\mu$ L/mL (20/108-18.5%), 20  $\mu$ L/mL (8/108-7.4%), and higher than 20  $\mu$ L/mL (10/108-9.3%). Based on the results obtained, Phyto-L has antibacterial activity on EPEC strains. Therefore, in field applications, Phyto-L should be useful in limiting the *E. coli* load in the rabbit gut, preventing the occurrence of colibacillosis. Moreover, considering that  $10^4$ – $10^5$  CFU/g of feces is the charge of *E. coli* normally present in the intestinal contents of rabbits under physiological conditions, it is possible that lower dosages than those found in this study may be effective in preventing the disease in rabbit farms.

**Abstract:** Colibacillosis, caused by enteropathogenic *Escherichia coli* (EPEC), is one of the most common diseases in rabbit farms, resulting in economic losses due to mortality and decrease in production. Until recently, antimicrobials were used to both treat and prevent disease on livestock farms, leading to the possible risk of antimicrobial resistance (AMR) and the selection of multidrug-resistant (MDR) bacteria. Therefore, interest in alternative control methods, such as the use of natural substances, has increased in the scientific community. The aim of this study was to evaluate the antimicrobial efficacy of Phyto-L (Pro Tech s.r.l.), a product containing organosulfur compounds (OSCs) such as propyl propane thiosulfonate (PTSO) from *Allium* spp., against 108 strains of *E. coli* isolated from rabbits with colibacillosis from 19 farms. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of Phyto-L were assessed. Bacterial suspensions with a charge of  $10^8$  CFU/mL, corresponding to those found in the rabbit gut under pathologic conditions, were tested with different concentrations from 20 to 0.15  $\mu$ L/mL of Phyto-L. For each strain, the MIC and concentrations above the MIC were plated on Tryptic Soy agar (TSA) without Phyto-L to assess the MBCs. MIC and MBC values ranged from 1.25 to 5  $\mu$ L/mL and 1.25 to 20  $\mu$ L/mL, respectively, depending on the strain tested. The data showed an interesting antibacterial activity of Phyto-L against EPEC strains. Therefore, this product could be effective in preventing colibacillosis in field application, especially considering that  $10^4$ – $10^5$  CFU/g of feces is the amount of *E. coli* usually found in the gut contents of rabbits under physiological condition.



**Citation:** D'Amico, F.; Casalino, G.; Dinardo, F.R.; Schiavitto, M.; Camarda, A.; Romito, D.; Bove, A.; Circella, E. Antimicrobial Efficacy of Phyto-L, Thiosulfonate from *Allium* spp. Containing Supplement, against *Escherichia Coli* Strains from Rabbits. *Vet. Sci.* **2023**, *10*, 411. <https://doi.org/10.3390/vetsci10070411>

Academic Editors: Patrick Butaye and Reta Duguma Abdi

Received: 26 April 2023

Revised: 7 June 2023

Accepted: 20 June 2023

Published: 23 June 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Keywords:** colibacillosis; rabbit; *Escherichia coli*; organosulfur compounds; antimicrobial efficacy; *Allium*

---

## 1. Introduction

Enteric and respiratory diseases are the main causes of mortality and production loss in meat rabbitries [1]. Colibacillosis is the most common intestinal disease. The agent of colibacillosis, *Escherichia coli* (*E. coli*), is a Gram-negative, rod-shaped, aerobic and facultative anaerobic, non-spore-forming coliform bacterium. *E. coli* may be responsible for disease in several animal species, including humans, cattle, pigs, sheep, goats, poultry, and rabbits. As in most animal species, *Escherichia coli* (*E. coli*) is a normal component of rabbit digestive flora [2]. The proliferation of *E. coli* in ileocecal contents occurs especially in post-weaning rabbits, causing diarrhea and economic decline due to weight loss and 20–30% mortality [3], which may be higher if associated with certain serotypes of *E. coli* [4]. Clinical signs may vary depending on the severity of the infection, immune status, and age of the rabbit. Colibacillosis usually occurs as acute enteritis in young rabbits and is typically characterized by the sudden onset of diarrhea, which appears watery, yellow, and may contain mucus. In addition, lethargy, dehydration, hypothermia, and anorexia are observed. Death occurs within 24 to 48 h of the onset of clinical signs. In adult rabbits, colibacillosis may evolve into chronic enteritis, and recurrent episodes of diarrhea and weight loss are found. Based on clinical symptoms observed in animals and virulence-associated genes, *E. coli* strains are classified into different pathotypes responsible for intestinal or extra-intestinal syndromes. Notably, the *E. coli* attachment and effacing (A/E) pathotype includes both enterohemorrhagic (EHEC) and enteropathogenic (EPEC) strains [5–11]. Enterohemorrhagic (EHEC) strains share two primary virulence factors: the pathogenicity island ‘LEE’ and prophages encoding one or more Shiga toxins [12]. Enteropathogenic *E. coli* (EPEC) strains responsible for colibacillosis in rabbits are among the major diarrheal *E. coli* pathotypes causing attachment and effacement (A/E) lesions, with the classic definition of intimate adhesion and effacement of intestinal microvilli. Their virulence is related to the possession of intimin (*eae* gene) [13] and bundle-forming pili (*bfp* gene) [14], (*af/r1* and *af/r2* genes) [15]. Another way to determine the enteropathogenicity of *E. coli* is to assess serogroup and sugar fermentation ability (biotype), targeted to establishing a link between biotype/serotype and rabbit mortality [3].

Treatment of colibacillosis involves the use of necessary drugs to control the bacterial infection and prevent secondary complications. The most used antibiotics are enrofloxacin and trimethoprim–sulfamethoxazole [16]. The choice of antibiotic should be based on antibiogram results, considering the specific susceptibility level of the bacterial strain detected in the disease outbreak [17]. In addition, monitoring of *E. coli* strains in rabbit populations is important to minimize the risk of selecting resistant strains [18]. Prevention of colibacillosis in rabbit farms is based on implementing biosecurity measures and improving husbandry practices [19]. Considering that colibacillosis is a disease that may be affected by several predisposing factors, it is relevant to ensure suitable ventilation and maintain good environmental hygiene conditions by regularly cleaning and disinfecting cages and equipment, such as feeders and troughs; avoid overcrowding and ensure proper handling of rabbits to minimize stress; and provide adequate nutrition by feeding rabbits balanced diets containing correct amounts of fiber. In addition, an appropriate weaning age for bunnies should be adopted [19]. Vaccine prophylaxis is not as widespread on rabbit farms as on poultry ones, essentially because of the lack of confidence that many farmers have in this method of prevention, owing to the cost of vaccines, the antigenic variability of disease-causing bacteria, and the presence of complex, multifactorial agents that may affect the effectiveness of the intervention [20].

Until recently, antibiotics have been widely used to prevent colibacillosis in the rabbit industry. Considering that for some antibiotics, a positive relationship has been found

between antimicrobial consumption and antimicrobial resistance in bacteria isolated from animals and humans, European legislation has drastically restricted the use of antibiotics on livestock for preventive purposes [21]. Therefore, a growing interest in alternative methods of infectious disease control has been observed. The possibility of using natural substances or their derivatives as an alternative to antibiotics has prompted the scientific community to investigate their potential effectiveness [22]. Among them, *Allium* spp. have attracted great interest in human medicine [23] because of their various biological functions, such as anti-inflammatory, antiatherosclerosis, antidiabetic, antimutagenic, anticarcinogenic, antioxidant, and immunomodulatory activities [24,25]. *Allium* spp. also seems to have antimicrobial properties against several pathogens [26–29]. The pharmacological effects of garlic and onion are related to their organosulfur compounds such as thiosulfonates [30,31], which are responsible for the typical pungent smell and healing properties [32]. When the plant tissues are disrupted, several thiosulfonate compounds containing combinations of allyl, methyl, or propyl groups are produced by enzymatic hydrolysis. Allyl-2propenylthiosulfinate is synthesized from alliin (S-allyl-L-cysteine sulfoxide) and, together with diallyl sulfide and its derivatives, constitutes one of the most important biologically active compounds found in garlic [33–37]. Thiosulfates are composed of sulfur atoms covalently bonded to other sulfur atoms and are unstable compounds that are easily oxidized in air [38], and their biological action appears to be linked to the number of sulfur atoms present [35,39,40]. It is known that through this instability, they participate in the activation and inactivation of enzymes, modify cellular protein activity [41], have a radioprotective effect by removing free radicals, inhibit the growth of tumor cells, and have a detoxifying and anti-aggregating effect on both human and canine platelets [42–44]. Concerning their mechanism of action, thiosulfates are able to inhibit the mitochondrial electron transport chain by reducing oxygen consumption and mitochondrial membrane potential and the amount of cellular ATP, resulting in toxicity to yeasts such as *Saccharomyces cerevisiae* [45]. Diallyl sulfide can penetrate the cell membrane, causing loss of cell integrity and the ability to synthesize ATP and resulting in bacterial lysis, inactivation of metabolic proteins, and inhibition of protein synthesis in both *Campylobacter jejuni* and *Helicobacter pylori* [46,47]. It is also capable of inhibiting the growth of *Klebsiella pneumoniae*, *Salmonella typhimurium*, and *Helicobacter pylori* by interfering with the activity of enzymes, including the arylamine N-acetyltransferase necessary to keep the bacterial cell metabolically active and therefore alive [39,48].

In our study, we tested the antimicrobial efficacy of a commercial product (Phyto-L) containing OSCs as thiosulfonates from *Allium* spp. against 108 strains of *E. coli* isolated from rabbits with colibacillosis from 19 farms. In order to provide a scientific basis for effective application in the rabbit industry, the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of Phyto-L were assessed.

## 2. Materials and Methods

### 2.1. Organosulfur Compounds

Phyto-L, supplied by Pro Tech Animal Nutrition s.r.l. (Via Zerbi, 47, Carbonara Scrivia, AL, Italy), was used to test antimicrobial efficacy. This product contains organosulfur compounds such as PTSO at a concentration of 170,000 µg/mL, supported on an inert carrier (glyceryl polyethylene glycol ricinoleate-E-484).

### 2.2. Bacterial Strains Used for the Study

The study was carried out in vitro on 108 *E. coli* strains from rabbits. All strains were previously collected in a period ranging from 2006 to 2023 and stored at –20 °C in Brucella broth and glycerol (10%) in the bacterial collection of the Avian Diseases Unit of the Department of Veterinary Medicine (DVM), University of Bari, Italy. The strains were previously isolated from the cecum contents of weaned rabbits that died from enteritis at ages ranging from 32 to 60 days. Rabbits were from 19 intensive rabbit farms in central and southern Italy. *E. coli* strains were identified as EPEC based on the detection of *eae* and *afr2*

genes by polymerase chain reaction (PCR) according to protocols already described [15,17]. All strains were grown on tryptic soy agar (TSA) (OXOID, Basingstoke, UK) at 37 °C overnight before performing the analyses.

### 2.3. Determination of Minimal Inhibitory Concentrations (MIC)

According to CLSI standards [49], a 0.5 McFarland suspension corresponding to  $1-2 \times 10^8$  CFU/mL was prepared for each strain. Mueller Hinton Broth (Oxoid) was prepared, reconstituted according to the manufacturer's instructions, and autoclaved at 121 °C for 15 min. The broth was brought to a temperature of 50 °C in a thermostatic bath. Phyto-L, previously diluted in DMSO in the ratio of 9:1 (9 parts of Phyto-L for one part of DMSO) according to [50–52], was added to the broth at concentrations ranging from 0.15 to 20 µL/mL (0.15, 0.3, 0.6, 1.25, 2.5, 5, 10, and 20 µL/mL). The broths were dispensed into 0.6 mL Eppendorf tubes, aliquoting 100 µL per tube.

Ten microliters of each bacterial suspension ( $1-2 \times 10^8$  CFU/mL) was added to the Eppendorf tubes containing broths with different concentrations of Phyto-L. As a positive control of bacterial growth, 10 µL of each bacterial suspension was inoculated into the broth containing DMSO at the highest concentration (0.2% DMSO) used in the trials. The contents of the Eppendorf tubes were mixed by automated vortexing and incubated at 37 °C for 24 h under aerobic conditions. Inhibition or growth of bacteria was interpreted according to the clarity or turbidity of the inoculated broths, respectively. The MIC was identified as the minimum concentration of Phyto-L at which the broth appeared clear. Each experiment was carried out twice.

### 2.4. Determination of Minimal Bactericidal Concentrations (MBC)

MBC determination was performed according to NCCLS [53], with some modifications. In detail, Petri plates containing Mueller Hinton agar (Oxoid), previously prepared according to the manufacturer's instructions and autoclaved at 121 °C for 15 min, were used. For each strain, the entire volume of broth corresponding to the MIC and all concentrations higher than the MIC were inoculated on Mueller Hinton agar.

All plates were incubated at 37 °C for 24 h under aerobic conditions. The MBC was identified as the lowest concentration at which no bacterial growth was observed on the culture medium.

## 3. Results

The MIC corresponded to 2.5 µL/mL for 70 out of 108 (64.8%) strains (Table 1). The MIC was 1.25 µL/mL for 37 (34.3%) strains and 5 µL/mL for one strain.

**Table 1.** MIC and MBC of Phyto-L found for 108 *E. coli* strains.

Phyto-L µL/mL (OSCs mg/mL)	MIC N° of Strains (%)	MBC N° of Strains (%)
>20 (>3.4)	0 (0)	10 (9.3)
20 (3.4)	0 (0)	8 (7.4)
10 (1.7)	0 (0)	20 (18.5)
5 (0.85)	1 (0.9)	9 (8.3)
2.5 (0.425)	70 (64.8)	46 (42.6)
1.25 (0.2125)	37 (34.3)	15 (13.9)
0.6 (0.102)	0 (0)	N.D. *
0.3 (0.051)	0 (0)	N.D.
0.15 (0.0255)	0 (0)	N.D.

\*ND: not determined.

The MBC was 1.25 and 2.5 µL/mL for 15 (13.9%) and 46 (42.6%) strains, respectively. It resulted in 10 µL/mL for 20 (18.5%) strains. The MBC was 20 µL/mL for 8 (7.4%) strains and higher than 20 µL/mL for 10 (9.3%) strains.

Considering the rabbit farms, the MIC corresponded to 1.25 µL/mL for strains identified in farms 3, 13, 14, 16, and 17 and to 2.5 µL/mL in farms 4, 5, 7, and 10 (Table 2). Conversely, MIC values were 1.25 or 2.5 µL/mL in farms 1, 2, 6, 8, 11. The MIC corresponded to 5 µL/mL only for a strain from farm 1.

**Table 2.** MIC and MBC of Phyto-L found for *E. coli* strains identified in the different farms.

Farm (N° of Tested Strains)	MIC						MBC					
	Phyto-L Concentrations (µL/mL)						Phyto-L Concentrations (µL/mL)					
	>20	20	10	5	2.5	1.25	>20	20	10	5	2.5	1.25
	N° of Strains (%)						N° of Strains (%)					
1 (25)	0 (0)	0 (0)	0 (0)	1 (4)	9 (36)	15 (60)	9 (36)	1 (4)	0 (0)	7 (28)	5 (20)	3 (12)
2 (26)	0 (0)	0 (0)	0 (0)	0 (0)	21 (80.8)	5 (19.2)	0 (0)	0 (0)	5 (19.2)	0 (0)	17 (65.4)	4 (15.4)
3 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (100)	0 (0)	0 (0)	3 (100)	0 (0)	0 (0)	0 (0)
4 (8)	0 (0)	0 (0)	0 (0)	0 (0)	8 (100)	0 (0)	0 (0)	1 (12.5)	5 (62.5)	0 (0)	2 (25)	ND *
5 (6)	0 (0)	0 (0)	0 (0)	0 (0)	6 (100)	0 (0)	0 (0)	0 (0)	3 (50)	0 (0)	3 (50)	ND
6 (7)	0 (0)	0 (0)	0 (0)	0 (0)	5 (71.4)	2 (28.6)	0 (0)	2 (28.6)	1 (14.3)	0 (0)	2 (28.6)	2 (28.6)
7 (2)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	0 (0)	0 (0)	2 (100)	0 (0)	0 (0)	0 (0)	ND
8 (13)	0 (0)	0 (0)	0 (0)	0 (0)	11 (84.6)	2 (15.4)	0 (0)	0 (0)	0 (0)	0 (0)	11 (84.6)	2 (15.4)
10 (3)	0 (0)	0 (0)	0 (0)	0 (0)	3 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (100)	ND
11 (2)	0 (0)	0 (0)	0 (0)	0 (0)	1 (50)	1 (50)	0 (0)	2 (100)	0 (0)	0 (0)	0 (0)	0 (0)
13 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	1 (50)	0 (0)	1 (50)	0 (0)	0 (0)	0 (0)
14 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)
16 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)
17 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	0 (0)	2 (100)	0 (0)	0 (0)	0 (0)	0 (0)

\* ND: Not determined.

In certain cases, such as farms 8, 10, 14, and 16, similar MBC and MIC values were observed. As expected, the susceptibility to the product varied depending on the strain isolated from each farm.

The highest variability in susceptibility to the product was found when testing strains from farm 1 (Table 3).

**Table 3.** MIC and MBC values found for each *E. coli* strain tested from farm 1.

Strain	MIC						MBC					
	Phyto-L Concentrations (µL/mL)						Phyto-L Concentrations (µL/mL)					
	>20	20	10	5	2.5	1.25	>20	20	10	5	2.5	1.25
1	-	-	-	-	-	+	-	-	-	+	-	-
2	-	-	-	-	-	+	-	-	-	-	+	-
3	-	-	-	-	-	+	-	-	-	-	-	+
4	-	-	-	-	-	+	-	-	-	-	-	+
5	-	-	-	-	-	+	-	-	-	-	-	+
6	-	-	-	-	-	+	-	-	-	+	-	-
7	-	-	-	-	-	+	-	-	-	-	+	-
8	-	-	-	-	+	-	+	-	-	-	-	-
9	-	-	-	-	+	-	+	-	-	-	-	-
10	-	-	-	-	-	+	+	-	-	-	-	-
11	-	-	-	-	+	-	-	-	-	+	-	-
12	-	-	-	-	+	-	+	-	-	-	-	-
13	-	-	-	-	-	+	-	-	-	-	+	-
14	-	-	-	-	-	+	-	-	-	+	-	-
15	-	-	-	-	+	-	-	-	-	+	-	-
16	-	-	-	-	+	-	-	-	-	-	+	-
17	-	-	-	+	-	-	+	-	-	-	-	-
18	-	-	-	-	+	-	-	+	-	-	-	-



Table 3. Cont.

Strain	MIC						MBC					
	Phyto-L Concentrations ( $\mu\text{L}/\text{mL}$ )						Phyto-L Concentrations ( $\mu\text{L}/\text{mL}$ )					
	>20	20	10	5	2.5	1.25	>20	20	10	5	2.5	1.25
19	-	-	-	-	-	+	-	-	-	+	-	-
20	-	-	-	-	+	-	+	-	-	-	-	-
21	-	-	-	-	-	+	+	-	-	-	-	-
22	-	-	-	-	-	+	-	-	-	-	+	-
23	-	-	-	-	-	+	+	-	-	-	-	-
24	-	-	-	-	-	+	+	-	-	-	-	-
25	-	-	-	-	+	-	-	-	-	+	-	-

#### 4. Discussion

Based on the results of this study, Phyto-L effectively inhibited the growth of *E. coli* in rabbits, with MIC values ranging from 1.25 to 5  $\mu\text{L}/\text{mL}$ , depending on the strain tested. This finding is of interest because the strains were tested in a bacterial load of  $10^8$  UFC/mL, which is the amount of *E. coli* detected per g of feces in rabbits affected by colibacillosis [54], whereas  $10^4$  or  $10^5$  UFC/mL/g of feces is normally found in the intestinal contents of rabbits under physiological conditions [55]. A previous study performed using garlic against *Salmonella* evidenced that lower concentrations of garlic were inhibitory against lower loads of bacteria [26]. In addition, the gut microbiota limits the proliferation of *E. coli* in rabbits under physiological conditions [56]. The immunomodulatory effect of *Allium* spp. also improves the activity of the intestinal microbiota as well as the production parameters of rabbits [57,58]. It is therefore very likely that when combined with the action of the intestinal microflora, the efficacy of Phyto-L in the prevention of colibacillosis in rabbit flocks may increase, leading to the use of lower dosages under field conditions than those suggested by the MIC values found in our study.

In addition, Phyto-L showed bactericidal effects on *E. coli* strains from rabbits with MBC values ranging from 1.25 up to 20  $\mu\text{L}/\text{mL}$ , which was in accordance with other studies in vitro [59,60]. This bactericidal effect indicated that the product could be effective not only in the prevention but also in the treatment of colibacillosis when used at higher doses. The bactericidal effect may depend on the structural characteristics of various microorganisms that influence their susceptibility to *Allium* components [60–67].

Concerning the inhibitory efficacy of Phyto-L found on strains tested in vitro, similar results have been observed in other studies using *Allium* spp. against various bacteria [26,68–70]. MIC values obtained for *E. coli*, *Staphylococcus aureus*, *Pseudomonas* and *Salmonella enterica* serovar Typhi [68], *Streptococcus mutans* [69], and *Salmonella* e. sub e. ser. Enteritidis [26,71] ranged from 0.02 to 6.25 mg/mL of garlic, depending on the bacterial species. Another study showed the antimicrobial efficacy of garlic against *S. aureus* if garlic was in concentrations above 7.50 mg/mL [59]. In addition to the bacterial species and bacterial load tested, variability in efficacy values may also be due to the laboratory methods used for investigation and the treatment of the natural substance before testing, which may affect the stability of allicin [72], the main active ingredient in garlic. Other organosulfur compounds such as PTSO have demonstrated a significant antimicrobial activity against multidrug-resistant isolates of *E. coli* and other *Enterobacteriaceae* spp. with MIC values in the range of 64–128  $\mu\text{g}/\text{mL}$  [73]. In addition, the same authors demonstrated a higher activity against Gram-positive bacteria such as *S. aureus* and reported the antimicrobial activity of PTSO via the gas phase [74]. Other previous studies have reported the in vitro bactericidal activity of thiosulfates against *E. coli* and *Salmonella typhimurium* in pig feces [75]. Recently, the antibacterial activity of PTSO was also described against fish pathogens [76].

In our study, the inhibitory efficacy of Phyto-L varied according to the strain tested, even when identified in rabbits from the same herd. This finding agreed with another study performed on *E. coli* and *S. aureus* strains, where similar MIC values were shown between

the two different bacterial species, whereas MIC variability from 4 to 8 mg/mL of garlic was found within each species, depending on the strain [70].

Natural substances usually show efficacy at dosages higher than those referred to for antibiotic molecules and, in addition, require longer administration times. *Allium* spp. has been found to be effective in the treatment and prevention of *E. coli* infections in chickens [63]. In broilers, administration results in a reduction of intestinal coliforms, as well as improved production performance [77]. A study of chickens reported the antimicrobial efficacy of garlic after administration for 56 days [78]. In addition, other in vivo studies in broilers fed with similar compounds found antimicrobial activity against *E. coli* and *Salmonella*. Furthermore, an improvement in body weight was observed in animals fed a diet with an *Allium* product [57]. A comparative study in rabbit farms evaluated the antimicrobial efficacy of garlic and florfenicol (FFC), a broad-spectrum antibiotic, against *E. coli* serotype O55:H7 [79,80]. Separate groups of rabbits were administered FFC for 5 days and garlic for 14 days, starting 7 days before the challenge infection and up to 7 days after infection. Compared with the control group, a reduction in symptoms and mortality was observed in both treated groups, as well as the maintenance of better productive performance and a reduction in fecal excretion of the *E. coli* strain used for infection. However, higher interferon-gamma (IFN- $\gamma$ ) and phagocyte levels were found in the garlic-treated group.

Moreover, the efficacy of Phyto-L could be enhanced by its combination with other natural products. In vitro, thyme, peppermint, sage, black pepper, and garlic showed a greater antimicrobial effect against *Bacillus subtilis* and *Salmonella* Enteritidis when combined rather than analyzed individually [81]. A mixture consisting of organic acids and cinnamon administered through the feed in turkey flocks resulted in the reduction of lesions induced by an antibiotic-resistant strain of *E. coli* 078 and a reduction in the intestinal concentration of the germ [82].

In any case, the use of natural substances could be a viable alternative to the use of antibiotics, especially on rabbit farms, where antimicrobial consumption (ACM) is the highest among food-producing animals [83]. The widespread use of antibiotics to prevent infectious diseases in animals increases the risk of antimicrobial resistance [84,85], and medicated feed containing antibiotics, widely used in the past, may have contributed to the selection of antibiotic-resistant bacterial populations in the environment and in animals [86]. More recently, antimicrobial consumption in rabbit breeding decreased with some drugs, although the use of substances such as fluoroquinolones increased [21]. Minimizing antibiotic use and finding alternative strategies for infection control are essential steps for reducing antimicrobial resistance. Therefore, in line with the European directives, Regulation (EU) 2019/6 and the circular n. 1/2022 on the guidelines for the prudent use of antibiotics in breeding rabbits for meat production, it is useful to increase the use of natural substances. Considering that colibacillosis is affected by several environmental and management factors, the association between the proper application of biosecurity and hygiene measures in rabbit farm management and the administration of natural substances is very relevant.

**Author Contributions:** Conceptualization, E.C.; methodology, E.C. and D.R.; validation, A.B.; investigation, F.D., G.C., A.B. and D.R.; formal analysis, F.R.D.; data curation, F.D. and M.S.; writing-original draft preparation, F.D., G.C. and E.C.; visualization A.C.; supervision E.C. and M.S.; writing-review and editing, E.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** No new data were created or analyzed in this study. Data sharing is not applicable to this article.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Kylie, J.; Brash, M.; Whiteman, A.; Tapscott, B.; Slavic, D.; Weese, J.S.; Turner, P.V. Biosecurity practices and causes of enteritis on Ontario meat rabbit farms. *Can. Vet. J.* **2017**, *58*, 571–578.
2. Milon, A.; Oswald, E.; De Rycke, J. Rabbit EPEC: A model for the study of enteropathogenic Escherichia coli. *Vet. Res.* **1999**, *30*, 203–219. [[PubMed](#)]
3. Camguilhem, R.; Milon, A. Biotypes and O serogroups of Escherichia coli involved in intestinal infections of weaned rabbits: Clues to diagnosis of pathogenic strains. *J. Clin. Microbiol.* **1989**, *27*, 743–747. [[CrossRef](#)] [[PubMed](#)]
4. Hamed, A.M.; Eid, A.A.; El-Bakrey, R.M. A review of rabbit diseases in Egypt. *Wartazoa* **2013**, *23*, 185–194.
5. Zhu, C.; Agin, T.S.; Elliott, S.J.; Johnson, L.A.; Thate, T.E.; Kaper, J.B.; Boedeker, E.C. Complete nucleotide sequence and analysis of the locus of enterocyte Effacement from rabbit diarrheagenic Escherichia coli RDEC-1. *Infect. Immun.* **2001**, *69*, 2107–2115. [[CrossRef](#)] [[PubMed](#)]
6. Marchés, O.; Ledger, T.N.; Boury, M.; Ohara, M.; Tu, X.; Goffaux, F.; Mainil, J.; Rosenshine, I.; Sugai, M.; De Rycke, J.; et al. Enteropathogenic and enterohemorrhagic Escherichia coli deliver a novel effector called Cif, which blocks cell cycle G2/M transition. *Mol. Microbiol.* **2003**, *50*, 1553–1567. [[CrossRef](#)] [[PubMed](#)]
7. Schmidt, H.; Hensel, M. Pathogenicity islands in bacterial pathogenesis. *Clin. Microbiol. Rev.* **2004**, *17*, 14–56. [[CrossRef](#)]
8. Bertin, Y.; Boukhors, K.; Livrelli, V.; Martin, C. Localization of the insertion site and pathotype determination of the locus of enterocyte effacement of shiga toxin-producing Escherichia coli strains. *Appl. Environ. Microbiol.* **2004**, *70*, 61–68. [[CrossRef](#)]
9. Thomas, N.A.; Deng, W.; Puente, J.L.; Frey, E.A.; Yip, C.K.; Strynadka, C.J.; Finlay, B.B. CesT is a multi-effector chaperone and recruitment factor required for the efficient type III secretion of both LEE- and non-LEE-encoded effectors of enteropathogenic Escherichia coli. *Mol. Microbiol.* **2005**, *57*, 1762–1779. [[CrossRef](#)]
10. Garrido, P.; Blanco, M.; Moreno-Paz, M.; Briones, C.; Dahbi, G.; Blanco, J.; Blanco, J.; Parro, V. STEC-EPEC oligonucleotide microarray: A new tool for typing genetic variants of the LEE pathogenicity island of human and animal Shiga toxin-producing Escherichia coli (STEC) and enteropathogenic E. coli (EPC) strains. *Clin. Chem.* **2006**, *52*, 192–201. [[CrossRef](#)]
11. Luo, W.; Donnenberg, M.S. Interactions and predicted host membrane topology of the enteropathogenic Escherichia coli translocator protein EspB. *J. Bacteriol.* **2011**, *193*, 2972–2980. [[CrossRef](#)] [[PubMed](#)]
12. Hartland, E.L.; Leong, J.M. Enteropathogenic and enterohemorrhagic E. coli: Ecology, pathogenesis, and evolution. *Front. Cell. Infect. Microbiol.* **2013**, *3*, 15. [[CrossRef](#)] [[PubMed](#)]
13. Blanco, M.; Blanco, J.E.; Alonso, M.P.; Blanco, J. Virulence Factors and O Groups of Escherichia Coli Isolates from Patients with Acute Pyelonephritis, Cystitis and Asymptomatic Bacteriuria. *Eur. J. Epidemiol.* **1996**, *12*, 191–198. [[CrossRef](#)]
14. Pearson, J.S.; Giogha, C.; Wong Fok Lung, T.; Hartland, E.L. The Genetics of Enteropathogenic Escherichia coli Virulence. *Annu. Rev. Genet.* **2016**, *50*, 493–513. [[CrossRef](#)]
15. Penteado, A.; Ugrinovich, L.; Blanco, J.; Blanco, M.; Blanco, J.; Mora, A.; Andrade, S.S.; Correa, A.F.; Pestana de Castro, A. Serotypes and virulence genes of Escherichia coli strains isolated from diarrheic and healthy rabbits in Brazil. *Vet. Microbiol.* **2002**, *89*, 41–51. [[CrossRef](#)] [[PubMed](#)]
16. Oglesbee, B.L.; Lord, B. *Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery*, 4th ed.; Saunders: Philadelphia, PA, USA, 2020; pp. 174–187.
17. Truong, W.R.; Hidayat, L.; Bolaris, M.A.; Nguyen, L.; Yamaki, J. The antibiogram: Key considerations for its development and utilization. *JAC Antimicrob. Resist.* **2021**, *3*, dlab060. [[CrossRef](#)]
18. Zhao, X.; Yang, J.; Ju, Z.; Chang, W.; Sun, S. Molecular characterization of antimicrobial resistance in Escherichia coli from rabbit farms in Tai'an, China. *Biomed Res. Int.* **2018**, *2018*, 1–7. [[CrossRef](#)]
19. Agnoletti, F. Update on rabbit enteric diseases: Despite improved diagnostic capacity, where does disease control and prevention stand. In Proceedings of the 10th World Rabbit Congress, Sharm El-Sheikh, Egypt, 3–6 September 2012.
20. Lavazza, A.; Grilli, G. Impiego dei vaccini nell'allevamento del coniglio. Attualità e nuove problematiche. In Proceedings of the Giornate di Coniglicoltura ASIC, Forlì, Italy, 9 April 2011.
21. Agnoletti, F.; Brunetta, R.; Bano, L.; Drigo, I.; Mazzolini, E. Longitudinal study on antimicrobial consumption and resistance in rabbit farming. *Int. J. Antimicrob. Agents.* **2018**, *51*, 197–205. [[CrossRef](#)]
22. Ibrahim, S.A.; Dharmavaram, S.R.; Seo, C.W.; Shahbazi, G. Antimicrobial activity of Bididobacterium Longum (NCFB2259) as influenced by spices. *Internet J. Food Saf.* **2004**, *2*, 6–8.
23. Chen, J.; Wang, F.; Yin, Y.; Ma, X. The nutritional applications of garlic (*Allium sativum*) as natural feed additives in animals. *PeerJ* **2021**, *9*, 11934. [[CrossRef](#)]
24. Cullen, S.P.; Monahan, F.J.; Callan, J.J.; O'Doherty, J.V. The effect of dietary garlic and rosemary on grower-finisher pig performance and sensory characteristics of pork. *IJAFR* **2005**, *44*, 57–67.
25. Kim, H.K. Garlic Supplementation Ameliorates UV-Induced Photoaging in Hairless Mice by Regulating Antioxidative Activity and MMPs Expression. *Molecules* **2016**, *21*, 70. [[CrossRef](#)] [[PubMed](#)]
26. Circella, E.; Casalino, G.; D'Amico, F.; Pugliese, N.; Dimuccio, M.M.; Camarda, A.; Bozzo, G. In Vitro Antimicrobial effectiveness tests using Garlic (*Allium sativum*) against Salmonella enterica Subspecies enterica Serovar Enteritidis. *Antibiotics* **2022**, *11*, 1481. [[CrossRef](#)] [[PubMed](#)]



27. Mouffok, A.; Bellouche, D.; Debbous, I.; Anane, A.; Khoualdia, Y.; Boubli, A.; Ahmad, S.D.; Lemaoui, T.; Benguerba, Y. Synergy of garlic extract and deep eutectic solvents as promising natural antibiotics: Experimental and COSMO-RS. *J. Mol. Liq.* **2023**, *375*, 121321. [CrossRef]
28. Sallam, K.; Raslan, M.T.; Sabala, R.F.; Abd-Elghany, S.; Mahros, M.A.; Elshebrawy, H. Antimicrobial Effect of Garlic Against Foodborne Pathogens in Ground Mutton; Department of Food Hygiene and Control, Faculty of Veterinary Medicine, Mansoura University, Mansoura, Egypt. SSRN 2023. Available online: <https://ssrn.com/abstract=4332276> (accessed on 20 June 2023).
29. Harris, J.C.; Cottrell, S.; Plummer, S.; Lloyd, D. Antimicrobial properties of *Allium sativum* (garlic). *Appl. Microbiol. Biotechnol.* **2001**, *57*, 282–286. [CrossRef]
30. Marefati, N.; Ghorani, V.; Shakeri, F.; Boskabady, M.; Kianian, F.; Rezaee, R.; Boskabady, M.H. A review of anti-inflammatory, antioxidant, and immunomodulatory effects of *Allium cepa* and its main constituents. *Pharm. Biol.* **2021**, *59*, 287–302. [CrossRef]
31. Tapiero, H.; Townsend, D.M.; Tew, K.D. Organosulfur compounds from alliaceae in the prevention of human pathologies. *Biomed. Pharmacother.* **2004**, *58*, 183–193. [CrossRef]
32. Macpherson, L.J.; Geierstanger, B.H.; Viswanath, V.; Bandell, M.; Eid, S.R.; Hwang, S.; Patapoutian, A. The pungency of garlic: Activation of TRPA1 and TRPV1 in response to allicin. *Curr. Biol.* **2005**, *15*, 929–934. [CrossRef] [PubMed]
33. Kyung, K.H.; Lee, Y.C. Antimicrobial activities of sulfur compounds derived from alk(en)yl-l-cysteine sulfoxides in *Allium* and Brassica. *Food Rev. Int.* **2001**, *17*, 183–198. [CrossRef]
34. Block, E.; Naganathan, S.; Putman, D.; Zhao, S.-H. *Allium* Chemistry: HPLC Analysis of Thiosulfates from Onion, Garlic, Wild Garlic (Ramsons), Leek, Scallion, Shallot, Elephant (Great-Headed) Garlic, Chive, and Chinese Chive. *J. Agric. Food Chem.* **1992**, *40*, 2418–2430. [CrossRef]
35. Chang, H.S.; Ko, M.; Ishizuka, M.; Fujita, S.; Yabuki, A.; Hossain, M.A.; Yamato, O. Sodium 2-propenyl thiosulfate derived from garlic induces phase II detoxification enzymes in rat hepatoma H4IIE cells. *Nutr. Res.* **2010**, *30*, 435–440. [CrossRef] [PubMed]
36. Lawson, L.D. *The Science and Therapeutic Application of Allium sativum L. and Related Species*, 2nd ed.; William and Wilkins: Baltimore, Maryland, 1996; pp. 37–107.
37. Casella, S.; Leonardi, M.; Melai, B.; Fratini, F.; Pistelli, L. The role of diallyl sulfides and dipropyl sulfides in the in vitro antimicrobial activity of the essential oil of Garlic, *Allium sativum* L., and Leek, *Allium porrum* L. *Phytother. Res.* **2012**, *27*, 380–383. [CrossRef] [PubMed]
38. Koike, S.; Ogasawara, Y. Sulfur Atom in its obund state is a unique element involved in physiological functions in mammals. *Molecules* **2016**, *21*, 1753. [CrossRef]
39. Tsao, S.M.; Yin, M.C. In vitro activity of garlic oil and four diallyl sulphides against antibiotic-resistant *Pseudomonas aeruginosa* and *Klebsiella pneumoniae*. *J. Antimicrob. Chemother.* **2001**, *47*, 665–670. [CrossRef] [PubMed]
40. Ross, Z.M.; O’Gara, E.A.; Hill, D.J.; Sleightholme, H.V.; Maslin, D.J. Antimicrobial properties of garlic oil against human enteric bacteria: Evaluation of methodologies and comparisons with garlic oil sulfides and garlic powder. *Appl. Environ. Microbiol.* **2001**, *67*, 475–480. [CrossRef]
41. Iciek, M.; Wlodek, L. Biosynthesis and biological properties of compounds containing highly reactive, reduced sulfane sulfur. *Pol. J. Pharmacol.* **2001**, *53*, 215–225.
42. Chang, H.S.; Yamato, O.; Yamasaki, M.; Maede, Y. Modulatory influence of sodium 2-propenyl thiosulfate from garlic on cyclooxygenase activity in canine platelets: Possible mechanism for the anti-aggregatory effect. *Prostaglandins Leukot. Essent. Fatty Acids* **2005**, *72*, 351–355. [CrossRef]
43. Chang, H.S.; Endoh, D.; Ishida, Y.; Takahashi, H.; Ozawa, S.; Hayashi, M.; Yabuki, A.; Yamato, O. Radioprotective effect of alk(en)yl thiosulfates derived from *Allium* vegetables against Dna damage caused by x-ray irradiation in cultured cells: Antiradiation potential of onions and garlic. *Sci. World J.* **2012**, *2012*, 1–5. [CrossRef]
44. Liu, C.T.; Chen, H.W.; Sheen, L.Y.; Kung, Y.L.; Chen, P.C.; Lii, C.K. Analytical methods-effect of garlic oil on hepatic arachidonic acid content and immune response in rats. *J. Agric. Food Chem.* **1998**, *46*, 4642–4647. [CrossRef]
45. Chen, Z.; Xia, Y.; Liu, H.; Liu, H.; Xun, L. The Mechanisms of Thiosulfate Toxicity against *Saccharomyces cerevisiae*. *Antioxidants* **2021**, *10*, 646. [CrossRef]
46. Lu, X.; Samuelson, D.R.; Rasco, B.A.; Konkol, M.E. Antimicrobial effect of diallyl sulphide on *Campylobacter jejuni* biofilms. *J. Antimicrob. Chemother.* **2012**, *67*, 1915–1926. [CrossRef]
47. O’Gara, E.A.; Hill, D.J.; Maslin, D.J. Activities of garlic oil, garlic powder, and their diallyl constituents against *Helicobacter pylori*. *Appl. Environ. Microbiol.* **2000**, *66*, 2269–2273. [CrossRef]
48. Chen, G.W.; Chung, J.G.; Ho, H.C.; Lin, J.G. Effects of the garlic compounds diallyl sulphide and diallyl disulphide on arylamine N-acetyltransferase activity in *Klebsiella pneumoniae*. *J. Appl. Toxicol.* **1999**, *19*, 75–81. [CrossRef]
49. CLSI. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard*, 7th ed.; Clinical Laboratory Standard Institute: Wayne, PA, USA, 2006.
50. Adiguzel, A.H.; Ozer, H.; Sokmen, M.; Gulluce, M.E.; Sokmen, A.; Kilic, H.; Sahin, F.; Baris, O. Antimicrobial and antioxidant activity of the essential oil and methanol extract of *Nepeta cataria*. *Pol. J. Microbiol.* **2009**, *58*, 69–76. [PubMed]
51. Moghaddam, A.M.; Shayegh, J.; Mikaili, P.; Sharaf, J.D. Antimicrobial activity of essential oil extract of *Ocimum basilicum* L. leaves on a variety of pathogenic bacteria. *J. Med. Plant. Res.* **2011**, *5*, 3453–3456.
52. Adiguzel, A.; Güllüce, M.; Şengül, M.; Öğütçü, H.; Şahin, F.; Karaman, İ. Antimicrobial effects of *Ocimum basilicum* (Labiatae) extract. *Turk. J. Biol.* **2005**, *29*, 155–160.

53. NCCLS. Available online: [file:///C:/Users/casal/Downloads/FDA-1975-N-0012-0317\\_attachment\\_192.pdf](file:///C:/Users/casal/Downloads/FDA-1975-N-0012-0317_attachment_192.pdf) (accessed on 1 September 1999).
54. Licois, D. Pathologie d'origine bactérienne et parasitaire chez le Lapin: Apports de la dernière décennie. *Cunicult. Mag.* **2010**, *37*, 35–49.
55. Padilha, M.T.; Licois, D.; Coudert, P. Frequency of the carriage and enumeration of *Escherichia coli* in caecal content of 15 to 49-day-old rabbits. In Proceedings of the 6th World Rabbit Congress, Toulouse, France, 9–12 July 1996.
56. Zhao, J.; Liu, Y.; Xiao, C.; He, S.; Yao, H.; Bao, G. Efficacy of phage therapy in controlling rabbit colibacillosis and changes in cecal microbiota. *Front. Microbiol.* **2017**, *8*, 957. [[CrossRef](#)]
57. Peinado, M.J.; Ruiz, R.; Echavarrri, A.; Rubio, L.A. Garlic derivative propyl propane thiosulfonate is effective against broiler enteropathogens in vivo. *Poult. Sci. J.* **2012**, *91*, 2148–2157. [[CrossRef](#)]
58. García-Rubio, V.G.; Bautista-Gómez, L.G.; Martínez-Castañeda, J.S.; Romero-Núñez, C. Multicausal etiology of the enteric syndrome in rabbits from Mexico. *Rev. Argent. Microbiol.* **2017**, *49*, 132–138. [[CrossRef](#)]
59. Shokradeh, M.; Ebadi, A.G. Antibacterial effect of Garlic (*Allium sativum*) on *Staphylococcus*. *Pak. J. Biol. Sci.* **2006**, *9*, 1577–1579. [[CrossRef](#)]
60. Mohsenipour, Z.; Hassanshahian, M. The Effects of *Allium sativum* extracts on biofilm formation and activities of six pathogenic bacteria. *J. Microbiol.* **2015**, *8*, 18971. [[CrossRef](#)] [[PubMed](#)]
61. Tynecka, Z.; Gos, Z.; Zajac, J. Energy-dependent efflux of cadmium coded by a plasmid resistance determinant in *Staphylococcus aureus*. *J. Bacteriol.* **1981**, *147*, 313–319. [[CrossRef](#)] [[PubMed](#)]
62. Leontiev, R.; Hohaus, N.; Jacob, C.; Gruhlke, M.C.; Slusarenko, A.J. A comparison of the antibacterial and antifungal activities of thiosulfinate analogues of allicin. *Sci. Rep.* **2018**, *8*, 1–19. [[CrossRef](#)]
63. Bayan, L.; Koulivand, P.H.; Gorji, A. Garlic: A review of potential therapeutic effects. *Avicenna J. Phytomed.* **2014**, *4*, 1.
64. Borlinghaus, J.; Albrecht, F.; Gruhlke, M.C.; Nwachukwu, D.; Slusarenko, A.J. Allicin: Chemistry and biological properties. *Molecules* **2014**, *18*, 12591–12618. [[CrossRef](#)]
65. Fujisawa, H.; Watanabe, K.; Suma, K.; Origuchi, K.; Matsufuji, H.; Seki, T.; Ariga, T. Antibacterial potential of garlic-derived allicin and its cancellation by sulfhydryl compounds. *Biosci. Biotechnol. Biochem.* **2009**, *73*, 1948–1955. [[CrossRef](#)]
66. Salehi, B.; Zucca, P.; Orhan, I.E.; Azzini, E.; Adetunji, C.O.; Mohammed, S.A.; Banerjee, S.K.; Sharopov, F.; Rigano, D.; Sharifi-Rad, J.; et al. Allicin and health: A comprehensive review. *Trends Food Sci. Technol.* **2019**, *86*, 502–516. [[CrossRef](#)]
67. Magryś, A.; Olender, A.; Tchórzewska, D. Antibacterial properties of *Allium sativum* L. against the most emerging multidrug-resistant bacteria and its synergy with antibiotics. *Arch. Microbiol.* **2021**, *203*, 2257–2268. [[CrossRef](#)]
68. Andualet, B. Combined antibacterial activity of stingless bee (*Apis mellipodae*) honey and garlic (*Allium sativum*) extracts against standard and clinical pathogenic bacteria. *Asian Pac. J. Trop. Biomed.* **2013**, *3*, 725–731. [[CrossRef](#)]
69. Jain, I.; Jain, P.; Bisht, D.; Sharma, A.; Srivastava, B.; Gupta, N. Comparative evaluation of antibacterial efficacy of six Indian plant extracts against *Streptococcus mutans*. *J. Clin. Diagn. Res.* **2015**, *9*, 725–731. [[CrossRef](#)] [[PubMed](#)]
70. Yadav, S.; Trivedi, N.A.; Bhatt, J.D. Antimicrobial activity of fresh garlic juice: An in vitro study. *Ayu* **2015**, *36*, 203. [[PubMed](#)]
71. Gull, I.; Saeed, M.; Shaukat, H.; Aslam, S.M.; Samra, Z.Q.; Athar, A.M. Inhibitory effect of *Allium sativum* and *Zingiber officinale* extracts on clinically important drug resistant pathogenic bacteria. *Ann. Clin. Microbiol. Antimicrob.* **2012**, *11*, 1–6. [[CrossRef](#)]
72. Belguith, H.; Kthiri, F.; Chati, A.; Abu Sofah, A.; Ben Hamida, J.; Landoulsi, A. Study of the effect of aqueous garlic extract (*Allium sativum*) on some *Salmonella* serovars isolates. *Emir. J. Food Agric.* **2010**, *22*, 189–206. [[CrossRef](#)]
73. Sorlozano-Puerto, A.; Albertuz-Crespo, M.; Lopez-Machado, I.; Ariza-Romero, J.J.; Baños-Arjona, A.; Exposito-Ruiz, M.; Gutierrez-Fernandez, J. In vitro antibacterial activity of propyl-propane-thiosulfinate and propyl-propane-thiosulfonate derived from *Allium* spp. against gram-negative and gram-positive multidrug-resistant bacteria isolated from human samples. *Biomed. Res. Int.* **2018**, *2018*, 1–10. [[CrossRef](#)]
74. Sorlozano-Puerto, A.; Albertuz-Crespo, M.; Lopez-Machado, I.; Gil-Martinez, L.; Ariza-Romero, J.J.; Maroto-Tello, A.; Baños-Arjona, A.; Gutierrez-Fernandez, J. Antibacterial and antifungal activity of propyl-propane-thiosulfinate and propyl-propane-thiosulfonate, two organosulfur compounds from *Allium cepa*: In vitro antimicrobial effect via the gas phase. *Pharmaceuticals* **2020**, *14*, 21. [[CrossRef](#)] [[PubMed](#)]
75. Ruiz, R.; García, M.P.; Lara, A.; Rubio, L.A. Garlic derivatives (PTS and PTS-O) differently affect the ecology of swine faecal microbiota in vitro. *Vet. Microbiol.* **2010**, *144*, 110–117. [[CrossRef](#)]
76. Cabello-Gómez, J.F.; Aguinaga-Casañas, M.A.; Falcón-Piñero, A.; González-Gragera, E.; Márquez-Martín, R.; Agraso, M.D.; Bermúdez, L.; Baños, A.; Martínez-Bueno, M. Antibacterial and antiparasitic activity of propyl-propane-thiosulfinate (PTS) and propyl-propane-thiosulfonate (PTSO) from *Allium cepa* against gilthead sea bream pathogens in in vitro and in vivo studies. *Molecules* **2022**, *27*, 6900. [[CrossRef](#)]
77. Munir, M.T. Effect of garlic on the health and performance of broilers. *Veterinaria* **2015**, *3*, 32–39.
78. Oladele, O.; Esan, O.; Akpan, I.; Enibe, F. Garlic feed inclusion and susceptibility of broiler chickens to infectious bursal disease. *J. Adv. Vet. Anim. Res.* **2018**, *5*, 275–281. [[CrossRef](#)]
79. Hassanin, F.S.; Reham, A.A.; Shawky, N.A.; Gomaa, W.M. Incidence of *Escherichia coli* and *Salmonella* in Ready to eat Foods. *Benha Vet. Med. J.* **2014**, *27*, 84–91.
80. Farag, V.M.; El-Shafei, R.A.; Elkenany, R.M.; Ali, H.S.; Eladl, A.H. Antimicrobial, immunological and biochemical effects of florfenicol and garlic (*Allium sativum*) on rabbits infected with *Escherichia coli* serotype O55: H7. *Vet. Res. Commun.* **2022**, *46*, 363–376. [[CrossRef](#)]

81. Al-Turki, A.I. Antibacterial effect of thyme, peppermint, sage, black pepper and garlic hydrosols against *Bacillus subtilis* and *Salmonella enteritidis*. *J. Food Agric. Environ.* **2007**, *5*, 92–94.
82. Parigi, M.; Massi, P.; Fiorentini, L.; Tosi, G.; Romboli, C.; Vandi, L.; Bocciero, R.; Fregnani, G. Valutazione dell'efficacia di una miscela di acidi organici e fitoterapici nel controllo dell'infezione da *Escherichia coli* nel tacchino. In Proceedings of the II Simposio Scientifico SIPA, Parma, Italy, 22 September 2017.
83. Moulin, G.; Chevance, A. Suivi des Ventes de Médicaments Vétérinaires Contenant des Antibiotiques en France en 2014. Rapport Annuel [Rapport de Recherche] Anses 2015. Ph.D. Thesis, 2015; pp. 1–39. Available online: <https://hal-anses.archives-ouvertes.fr/anses-01226391/document> (accessed on 20 June 2023).
84. Marshall, B.M.; Levy, S.B. Food animals and antimicrobials: Impacts on human health. *Clin. Microbiol. Rev.* **2011**, *24*, 718–733. [[CrossRef](#)] [[PubMed](#)]
85. Malhotra-Kumar, S.; Xavier, B.B.; Das, A.J.; Lammens, C.; Hoang, H.T.; Pham, N.T.; Goossens, H. Colistin-resistant *Escherichia coli* harbouring *mcr-1* isolated from food animals in Hanoi, Vietnam. *Lancet Infect. Dis.* **2016**, *16*, 286–287. [[CrossRef](#)] [[PubMed](#)]
86. European Union Regulation (EU) 2019/4 of the European Parliament. Available online: <https://eur-lex.europa.eu/legalcontent/EN/TXT/PDF> (accessed on 11 December 2018).

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.